Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR et al.
International Journal of Molecular Sciences, 2023
Pharmacogenomic profile of actionable molecular variants related to drugs commonly used in anesthesia: WES analysis reveals new mutations.
Parada-Márquez JF et al.
Frontiers in Pharmacology, 2023
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
In silico screening and analysis of nonsynonymous SNPs in human CYP1A2 to assess possible associations with pathogenicity and cancer susceptibility.
Navapour L et al.
Scientific Reports, 2021
Impact of peripheral mutations on the access channels of human cytochrome P450 1A2.
Ying B et al.
Journal of Biomolecular Structure & Dynamics, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.
Lewis BC et al.
Pharmacogenetics and Genomics, 2016
Prediction of three-dimensional structures and structural flexibilities of wild-type and mutant cytochrome P450 1A2 using molecular dynamics simulations.
Watanabe Y et al.
Journal of Molecular Graphics & Modelling, 2016
Functional characterization of 20 allelic variants of CYP1A2.
Ito M et al.
Drug Metabolism and Pharmacokinetics, 2015
Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A2*8, *15, and *16 (R456H, P42R, and R377Q).
Lim YR et al.
Biomolecules & Therapeutics, 2015
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM et al.
Pharmacology & Therapeutics, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression.
Palma BB et al.
The Pharmacogenomics Journal, 2010
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
Zhou SF et al.
Drug Metabolism Reviews, 2010
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.
Zhou SF et al.
The Aaps Journal, 2009
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
Zanger UM et al.
Analytical and Bioanalytical Chemistry, 2008
Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism.
Tiwari AK et al.
The Pharmacogenomics Journal, 2007
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T et al.
American Family Physician, 2007
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.
Ghotbi R et al.
European Journal of Clinical Pharmacology, 2007
Functional analysis of three CYP1A2 variants found in a Japanese population.
Saito Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
Tiwari AK et al.
The Pharmacogenomics Journal, 2005
Functional characterization of four allelic variants of human cytochrome P450 1A2.
Zhou H et al.
Archives of Biochemistry and Biophysics, 2004
Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer.
Tsukino H et al.
Journal of Cancer Research and Clinical Oncology, 2004
Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population.
Chevalier D et al.
Human Mutation, 2001